Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study

Chih Hung Hsu, Yoon Koo Kang, Tsai Shen Yang, Chia Tung Shun, Yu Yun Shao, Wu Chou Su, Jennifer Sandoval-Tan, Tzeon Jye Chiou, Kate Jin, Chiun Hsu, Ann Lii Cheng

研究成果: Article

34 引文 斯高帕斯(Scopus)

摘要

Objectives: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. This multicenter study across several Asian countries was to evaluate the safety and efficacy of the combination in this population. Methods: Patients with histology-proven HCC, advanced disease and Child-Pugh class A liver function received bevacizumab 5 mg/kg intravenously every 2 weeks and erlotinib 150 mg/day orally as first-line therapy. The primary end point was progression-free survival at 16 weeks (PFS-16W). The expression of epidermal growth factor receptor (EGFR), phospho-AKT and vascular endothelial growth factor, the microvessel density and the EGFR gene copy number in HCC tissues were correlated with treatment efficacy. Results: Fifty-one patients were enrolled. The PFS-16W was 35.3% (95% CI 22.4-49.9), the median PFS was 2.9 months (95% CI, 1.3-4.4) and the median overall survival was 10.7 months (95% CI, 6.2-15.2). Grade 3/4 toxicities were uncommon, including rash, acne (10% each), diarrhea (6%) and gastrointestinal bleeding (4%). None of the evaluated biomarkers correlated with disease control or PFS. Conclusions: Bevacizumab plus erlotinib showed good tolerability and modest activity in this Asian cohort. Further studies are warranted to identify the predictive biomarkers of this combination.

原文English
頁(從 - 到)44-52
頁數9
期刊Oncology (Switzerland)
85
發行號1
DOIs
出版狀態Published - 2013 七月 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

指紋 深入研究「Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study」主題。共同形成了獨特的指紋。

  • 引用此

    Hsu, C. H., Kang, Y. K., Yang, T. S., Shun, C. T., Shao, Y. Y., Su, W. C., Sandoval-Tan, J., Chiou, T. J., Jin, K., Hsu, C., & Cheng, A. L. (2013). Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study. Oncology (Switzerland), 85(1), 44-52. https://doi.org/10.1159/000350841